Protective effects of water-soluble low-molecular-weight β-(1,3-1,6)D-glucan purified from Aureobasidium pullulans GM-NH-1A1 against UFT toxicity in mice

Journal of Pharmacy and Pharmacology

Volumn 61, Issue 6, 2009, Pages 795-800

  Kimura, Yoshiyuki ^a   Sumiyoshi, Maho ^a   Suzuki, Toshio ^b  

^a EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Daiso Co Ltd   (Japan)

Author keywords

Adverse reaction; Anti tumour activity; Gastrointestinal toxicity; UFT; Water soluble low molecular weight glucan

Indexed keywords

BETA GLUCAN; DEXTRAN; UFT; WATER; ANTINEOPLASTIC AGENT; BETA 1,6 GLUCAN; BETA-1,6-GLUCAN; TEGAFUR; URACIL;

ADD ON THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUREOBASIDIUM PULLULANS; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG PURIFICATION; ENTERITIS; GASTROINTESTINAL TOXICITY; HISTOLOGY; HUMAN; HUMAN CELL; INTESTINE INJURY; MALE; MOUSE; MUCOSA INFLAMMATION; NONHUMAN; SMALL INTESTINE; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; BASIDIOMYCETES; CANCER TRANSPLANTATION; CHEMICALLY INDUCED DISORDER; CHEMISTRY; DRUG EFFECT; DRUG POTENTIATION; ENTEROPATHY; INTESTINE MUCOSA; MOLECULAR WEIGHT; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BASIDIOMYCOTA; BETA-GLUCANS; CELL LINE, TUMOR; DRUG SYNERGISM; INTESTINAL DISEASES; INTESTINAL MUCOSA; INTESTINE, SMALL; MALE; MICE; MICE, INBRED BALB C; MOLECULAR WEIGHT; MUCOSITIS; NEOPLASM TRANSPLANTATION; TEGAFUR; URACIL;

EID: 68849123464     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp/61.06.0013     Document Type: Article

References (34)

1. Wang SY et al. The anti-tumor effect of Ganoderma lucidium is mediated by cytokines released from activated macrophages and lymphocytes. Int J Cancer 1997; 70: 699-705.
2. Kim GY et al. Acidic polysaccharide isolated from Phellinus lintens enhances through the up-regulation of nitric oxide and tumor necrosis factor-α from peritoneal macrophages. J Ethnopharmacol 2004; 95: 69-76.
3. Ohno N et al. Antitumor β-glucan from the cultured fruit body of Agaricus blazei. Biol Pharm Bull 2001; 24: 820-828.
4. Oshima K et al. Orally administered β-1,6-D-polyglucose from Agaricus blazei results in tumor regression in tumor-bearing mice. Planta Med 2002; 68: 610-614.
5. Sanzen I et al. Nitric oxide-mediated antitumor activity induced by the extract from Grifola frondosa (Maitake mushroom) in a macrophage cell line, RAW 264.7. J Exp Clin Cancer Res 2001; 20: 591-597.
6. Kodama N et al. Effects of D-fraction, a polysacchride from Grifola frandosa, on tumor growth involve activation of NK cells. Biol Pharm Bull 2002; 25: 1647-1650.
7. Ohno N et al. Antitumor 1,3-β-glucan from cultured fruit body of Sparassis crispa. Biol Pharm Bull 2000; 23: 866-872.
8. Harada T et al. Effects of SCG, 1,3-β-D-glucan from Sparassis crispa on the hematopoietic response in cyclophosphamide induced leukopenic mice. Biol Pharm Bull 25: 931-939.
9. Ng ML, Yap AT. Inhibition of human colon carcinoma development by lentinan from Shitake mushrooms (Lentinus edodes). J Altern Complement Med 2002; 8: 581-589.
10. Taguchi T et al. Clinical efficacy of lentinan on neoplastic diseases. Adv Exp Med Biol 1983; 166: 181-187.
11. Fujimoto S et al. Clinical evaluation of SPG (schizophyllan) as a therapeutic adjuvant after surgery of gastric cancer-controlled study by an envelope method [in Japanese]. Gan To Kagaku Ryoho 1983; 10: 11135-11145.
12. Torisu M et al. Significant prolongation of disease-free period gained by oral polysaccharide Krestin (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol Immunother 1990; 31: 261-268.
13. Suzuki T et al. Production of high purified β-glucan from Aureobasidium pullulans and its characteristics. Food Function 2005; 2: 45-50.
14. Kimura Y et al. Antitumor and antimetastatic activity of a novel water-soluble low molecular weight β-1,3-D-glucan (branch β-1,6) isolated from Aureobasidium pulluans 1A1 strain black yeast. Anticancer Res 2006; 26: 4131-4142.
15. Kimura Y et al. Inhibitory effects of water-soluble low-molecular-weight β-(1,3-1,6) D-glucan purified from Aureobasisium pullulans GM-NH-1A1 strain on food allergic reactions in mice. Int Immunopharmacol 2007; 7: 963-972.
16. Kimura Y et al. Effects of water-soluble low-molecular-weight β-1,3-D-glucan (branch β-1,6) isolated from Aureobasidium pullulans 1A1 strain black yeast on restraint stress in mice. J Pharm Pharmacol 2007; 59: 1137-1144.
17. Duschisky R et al. The synthesis of 5-fluoropyrimidines. J Am Chem Soc 1957; 79: 4559-4560.
18. Heidelberg C, Ansfield FJ. Experimental and clinical use of fluorinated pyrimidines in cancer chemotherapy. Cancer Res 1963; 23: 1226-1243.
19. Seifert P et al. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer 1975; 36: 123-128.
20. Shah A et al. 5-FU infusion in advanced colorectal cancer: comparison of three dose schedules. Cancer Treat Rep 1985; 69: 739-742.
21. Caballero GA et al. Long-term, ambulatory, continuous infusion of 5-FU for the treatment of advanced adenocarcinomas. Cancer Treat Rep 1985; 69: 13-15.
22. Houghton JA et al. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine and 5-fluoro-2′-deoxyuridine. Cancer Res 1979; 39: 2406-2413.
23. Schuetz JD et al. 5-Fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity. Cancer Res 1984; 44: 1358-1363.
24. Kimura Y, Okuda H. Prevention by chitosan of myelotoxicity, gastrointestinal toxicity and immunocompetent organic toxicity induced by 5-fluorouracil without loss of antitumor activity in mice. Jpn J Cancer Res 1999; 90: 765-774.
25. Kimura Y et al. Antitumor activity and side effects of combined treatment with chitosan and cisplatin in sarcoma 180-bearing mice. J Pharm Pharmacol 2000; 52: 883-890.
26. Kimura Y et al. Antitumor activity and adverse reactions of combined treatment with chitosan and doxorubicin in tumor-bearing mice. J Pharm Pharmacol 2001; 53: 1373-1378.
27. Fujii S et al. Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gann 1978; 69: 763-772.
28. Fujii S et al. Effect of coadministration of uracil or cytosine on the antitumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5- fluorouracil and level of 5-fluorouracil in rodents. Gann 1979; 70: 209-214.
29. Idelevich E et al. Phase II study of UFT with leucovolin plus hepatic arterial infusion with irinotecan, 5-fluorouracil and leucovorin for non-resectable liver metastasis of colorectal cancer. Chemotherapy 2008; 55: 76-82.
30. Hisashige A et al. Cost-effectiveness of adjuvant chemotherapy with uracil-tegafur for curatively resected stage III rectal cancer. Br J Cancer 2008; 99: 1232-1238.
31. Lowry OH et al. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265-275.
32. Gianni AM et al. Recombinant human granulocyte-macrophage colony-stimulating factor reduces heamtologic toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol 1990; 8: 761-764.
33. Zielinski CC et al. The impact of new European Organisation for Research and Treatment of Cancer guidelines on the use of granulocyte colony-stimulating factor on the management of breast cancer patients. Eur J Cancer 2008; 44: 353-365.
34. Khan S et al. Impact of neutropenia on delivering planned chemotherapyfor solid tumors.Eur JCancerCare2008;17:19-25.